National Institute for Health and Care Excellence

Benefits of new Alzheimer’s treatment lecanemab are too small to justify the cost to the NHS

The benefits of the new Alzheimer’s drug lecanemab are too small to justify the costs, NICE said in draft guidance published today. Lecanemab (also called Leqembi and made by Eisai) is for slowing ...
The National Institute for Health and Care Excellence

MHRA and NICE aligned pathway: how it's working in practice

Although the aligned pathway is central to our work, the benefits of improved collaboration between MHRA and NICE go beyond it. A recent example is aficamten, a new daily pill for people with ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Digital technologies to support home monitoring of vision changes for people with advanced dry age-related macular degeneration: early-use assessment HTG781 17 September 2026 17 September 2026 ...
National Institute for Health and Care Excellence

Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy

Evidence-based recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-low metastatic or unresectable breast cancer after chemotherapy in adults. This guidance updates and replaces NICE ...
National Institute for Health and Care Excellence

Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer

Evidence Documents containing the evidence that was used to develop the recommendations. Supporting evidence Surveillance report 2024 exceptional surveillance of familial breast cancer: classification ...
National Institute for Health and Care Excellence

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19

This guideline has been updated and replaced by NICE rapid guideline on managing COVID-19 (NG191) ...
National Institute for Health and Care Excellence

Quality statement 2: Diagnosis of axial spondyloarthritis using imaging

Adults with suspected axial spondyloarthritis and an X‑ray that does not show sacroiliitis have an MRI using an inflammatory back pain protocol. No single test can diagnose axial spondyloarthritis.
National Institute for Health and Care Excellence

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years Technology appraisal guidance TA554 Published: 21 December 2018 ...
National Institute for Health and Care Excellence

Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable

There is a simple discount patient access scheme for daratumumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...